Mavacamten in adolescents with obstructive hypertrophic cardiomyopathy (Registro nro. 22747)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03218nam a2200289 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | eng |
| 100 ## - Autor | |
| Autor | Rossano, Joseph W. |
| Rol del Autor | Autor |
| 9 (RLIN) | 53796 |
| 245 ## - Titulo | |
| Titulo | Mavacamten in adolescents with obstructive hypertrophic cardiomyopathy |
| 300 ## - Páginas | |
| Paginación | páginas: 362-373 |
| 520 ## - Resumen | |
| Resumen | Background: Approved pharmacologic therapies for pediatric hypertrophic cardiomyopathy are lacking, and surgical intervention may be indicated in patients with left ventricular outflow tract obstruction. The efficacy and safety of mavacamten, a cardiac myosin inhibitor that is available for adults, warrant evaluation in adolescents.<br/>Methods: We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving symptomatic adolescents (12 to <18 years of age) with New York Heart Association class II or III obstructive hypertrophic cardiomyopathy. The patients were randomly assigned in a 1:1 ratio to receive mavacamten or placebo. The primary end point was the change from baseline to week 28 in left ventricular outflow tract pressure gradient provoked by the Valsalva maneuver.<br/>Results: A total of 44 patients underwent randomization; 23 patients (8 [35%] of whom were female) were assigned to mavacamten group, and 21 (5 [24%] of whom were female) were assigned to the placebo group. The mean (±SD) age of the patients was 14.7±1.7 years in the mavacamten group and 14.6±1.7 years in the placebo group, and the mean Valsalva left ventricular outflow tract gradient at baseline was similar in the two groups (78.4±34.1 mm Hg and 80.8±47.4 mm Hg, respectively). At week 28, the least-squares mean change in the Valsalva left ventricular outflow tract gradient was −48.5 mm Hg in the mavacamten group and −0.5 mm Hg in the placebo group (difference, −48.0 mm Hg; 95% confidence interval, −67.7 to −28.3; P<0.001). The incidence of adverse events was similar in the two groups. Two patients in each group had serious adverse events; in the mavacamten group, 1 patient had two episodes of syncope, and another had an inappropriate shock delivered by an implantable cardioverter–defibrillator; in the placebo group, 1 patient had chest pain, and another had depression with suicidal ideation. No patient had a reduction in the left ventricular ejection fraction to less than 50%. No deaths occurred during the trial.<br/>Conclusions: Among adolescent patients with obstructive hypertrophic cardiomyopathy, the reduction in left ventricular outflow tract obstruction was significantly greater with mavacamten than with placebo over a 28-week period. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | MEDICINA DEL ADOLESCENTE |
| 9 (RLIN) | 5533 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CARDIOLOGÍA |
| 9 (RLIN) | 11301 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | INSUFICIENCIA CARDIACA |
| 9 (RLIN) | 11699 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | PEDIATRIA |
| 9 (RLIN) | 6401 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CARDIOMIOPATÍA |
| 9 (RLIN) | 37409 |
| 700 ## - Autor Personal | |
| Autor Personal | Canter, Charles |
| 9 (RLIN) | 53797 |
| 700 ## - Autor Personal | |
| Autor Personal | Wolf, Cordula M. |
| 9 (RLIN) | 53798 |
| 700 ## - Autor Personal | |
| Autor Personal | Papez, Andrew |
| 9 (RLIN) | 53799 |
| 700 ## - Autor Personal | |
| Autor Personal | Gambra, Marta |
| 9 (RLIN) | 53800 |
| 700 ## - Autor Personal | |
| Autor Personal | Bryant, Randall M. |
| 9 (RLIN) | 53801 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22637 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM004 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-07-31 |
| Catalogador | SQB |
No hay ítems disponibles.